Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Bart A. Ploeger"'
Autor:
Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Publikováno v:
EClinicalMedicine, Vol 58, Iss , Pp 101917- (2023)
Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with mic
Externí odkaz:
https://doaj.org/article/607bb200b67a4b90be60f4ef3e49d300
Autor:
Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H. Prins, John Lettieri, David Mitchell, Funan Huang, Marcia S. Brose, Martin Schlumberger, Gerold Meinhardt, Carol E. A. Peña, Bart A. Ploeger
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the inci
Externí odkaz:
https://doaj.org/article/f459c9a764c849519f2e779c790d916b
Autor:
Liang Jin, Dean F. Rigel, Bart A Ploeger, Donald R. Stanski, Randy L. Webb, Michael E. Beil, David Louis Feldman, Olivier Luttringer, Meindert Danhof, Nelleke Snelder, Fumin Fu
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 360:356-367
Sphingosine 1-phosphate (S1P) receptor agonists are associated with cardiovascular effects in humans. This study aims to develop a systems pharmacology model to identify the site of action (i.e., primary hemodynamic response variable) of S1P receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ce883d1f06b138b232cac56fb91eff
https://doi.org/10.1124/jpet.116.236208
https://doi.org/10.1124/jpet.116.236208
Autor:
Henk-Jan Guchelaar, Oliver W. Ackaert, Rogier R. Press, Jaap J. Homan van der Heide, Meindert Danhof, Judith A.M. Wessels, Frederike J. Bemelman, Johan W. de Fijter, Dirk Jan A.R. Moes, Tahar van der Straaten, Bart A. Ploeger, Jan-Stephan F. Sanders, Cheikh Diack
Publikováno v:
British Journal of Clinical Pharmacology. 82:227-237
AIMS This study aimed at identifying pharmacological factors such as pharmacogenetics and drug exposure as new predictive biomarkers for delayed graft function (DGF), acute rejection (AR) and/or subclinical rejection (SCR). METHODS Adult renal transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b201f9b223b228bb8da4c1bca1238a6
https://doi.org/10.1111/bcp.12946
https://doi.org/10.1111/bcp.12946
Autor:
Meindert Danhof, Donald R. Stanski, Randy L. Webb, Bart A Ploeger, Michael E. Beil, Dean F. Rigel, Nelleke Snelder, Fumin Fu, Liang Jin, David Louis Feldman, Olivier Luttringer
Publikováno v:
British Journal of Pharmacology. 169:1510-1524
Background and purpose The homeostatic control of arterial BP is well understood with changes in BP resulting from changes in cardiac output (CO) and/or total peripheral resistance (TPR). A mechanism-based and quantitative analysis of drug effects on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bac90bfc7474d60f6f65804d008d86c8
https://doi.org/10.1111/bph.12190
https://doi.org/10.1111/bph.12190
Autor:
Joost de Jongh, Aziz Karim, Meindert Danhof, Graham Scott, Frances Stringer, Richard Urquhart, Bart A. Ploeger
Publikováno v:
The Journal of Clinical Pharmacology. 53:256-263
Sipoglitazar is a peroxisome proliferator–activated receptor α, δ, and γ agonist. During phase I, a wide distribution of clearance between individuals was observed. Hypothesized to result from a polymorphism in the uridine 5′-diphospate-glucur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::030f322f815e7a1b97e2620e355ea5df
https://doi.org/10.1177/0091270012447121
https://doi.org/10.1177/0091270012447121
Publikováno v:
The AAPS Journal. 14:543-553
One of the major challenges in the development of central nervous system (CNS)-targeted drugs is predicting CNS exposure in human from preclinical data. In this study, we present a methodology to investigate brain disposition in rats using a physiolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513b2422ef28cccb798f2f641e817abd
https://doi.org/10.1208/s12248-012-9366-1
https://doi.org/10.1208/s12248-012-9366-1
Autor:
Meindert Danhof, Elizabeth C. M. de Lange, Jasper Stevens, Piet H. van der Graaf, Bart A. Ploeger
Publikováno v:
Drug Metabolism and Disposition. 39:2275-2282
Intranasal (IN) administration could be an attractive mode of delivery for drugs targeting the central nervous system, potentially providing a high bioavailability because of avoidance of a hepatic first-pass effect and rapid onset of action. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fd74ada53715d1cb68e248fd8aee75a
https://doi.org/10.1124/dmd.111.040782
https://doi.org/10.1124/dmd.111.040782
Autor:
Hans de Fijter, Bart A. Ploeger, Meindert Danhof, T. van der Straaten, Henk-Jan Guchelaar, Hans van Pelt, Jan den Hartigh, Rogier R. Press
Publikováno v:
European Journal of Clinical Pharmacology, 66(6), 579-590
European Journal of Clinical Pharmacology
European Journal of Clinical Pharmacology
Purpose Optimal ciclosporin A (CsA) exposure in kidney transplant recipients is difficult to attain because of variability in CsA pharmacokinetics. A better understanding of the variability in CsA exposure could be a good means of individualizing the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b74018fcc15b284d8da83f814f07384
https://doi.org/10.1007/s00228-010-0810-9
https://doi.org/10.1007/s00228-010-0810-9
Autor:
Nigel J. M. Birdsall, Bart A. Ploeger, Piet H. van der Graaf, Harriet Sale, Carolyn Napier, Richard P. Butt, Nelleke Snelder, Neil Benson
Publikováno v:
British Journal of Pharmacology. 160:389-398
Background and purpose: Reboxetine is a clinically used antidepressant and is a racemic mixture of two enantiomers, SS- and RR-reboxetine. The aim of the work described in this manuscript was to determine the kinetics of binding of the RR- and SS-reb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5725d32e15a04dc25087d62e6014feaa
https://doi.org/10.1111/j.1476-5381.2010.00719.x
https://doi.org/10.1111/j.1476-5381.2010.00719.x